

# Nano Technology in the Creation of Vaginal Drug Delivery System Using Mucoadhesion and Thermogellation with Conjugation of S-Chitosan

Nousheen Nazeer

University of Azad and Jammu Kashmir, Muzaffarabad, Pakistan  
Corresponding Author's e-mail: scholar.shahzeb4@gmail.com

**Abstract**— This audit involves two detailed approaches, mucoadhesion and thermal gelling, which have been proposed to slow the vaginal mucosa from clinical devices or drug delivery frames to improve their viability. After a precise presentation the study manages the aforementioned transport frames of the vaginal condition and in particular the vaginal emissions which have a strong influence on the in vivo performance of the vaginal definitions. The usual rates (gels, tablets, suppositories and emulsions) and the new drug transport frames (small, nanoparticles) that are supposed to be similar or fundamental for the mucoadhesive frames. The effect of this is on the vaginal organization. The polar-based concepts (ethylene oxide-propylene oxide-ethylene oxide-oxide) and chitosan-based copolymers are investigated as thermosetting reinforcements for thermogellating reinforcements. The techniques employed in making mucoadhesive and thermogellating drug delivery structures useful are also briefly described.

**Keywords**— Mucoadhesion, nanoparticles, thermogellating, emulsions, suppositories oxide-propylene.

## 1. INTRODUCTION

Nanotechnologies seem to link the barriers of the organic and Physical sciences through the application of nanostructures to the different scientific fields. Exceptionally in drug delivery environments focused on nano-medicine, where certain particles are of great concern. The nanomaterials can be characterized as materials of 1 to 100 nm size, which affect Nano-acetic from biosafety and microfluidics to medicines and micro-marine transport tests to tissue construction.(Patricia Bento da Silva). Nanotechnology uses nanoscale enhancement operators to manufacture Nano-medicine. Nanoparticles dominate the field of biomedicine, which involves nanotechnology, drug delivery, biosafety and tissue engineering. Since nanoparticles contain materials that are formed at the nuclear or subatomic level, they are typically small Nano-species calculated. That means they can move around in the human body more freely compared to larger materials.(E. P.-S.-M.-Z.-E.-G. Gerardo Leyva-Gómez). Particles valued in the Nano range have additional unique, synthetic, mechanical, attractive, electrical and natural properties. Nano medicine has been very recently refreshed as nanostructures can be used as carriers by incorporating medication or binding and delivering useful medications to more controlled target tissues.(Laura M. Ensign). Nano medicine is a growing field that uses nanoscience information and methods in clinical science as well as to predict and cure diseases. It encrypts the use of Nanoparticles dominate the field of biomedicine, which involves

nanotechnology, drug delivery, biosafety and tissue engineering. Since nanoparticles contain materials that are formed at the nuclear or subatomic level, they are typically small Nano-species calculated. That means they can move around in the human body more freely compared to larger materials. (Barbara Vigani).

These liposomes and micelles may contain inorganic nanoparticles such as gold or nanoparticles which are attractive. These properties allow the use of inorganic nanoparticles to expand, with a focus on sedative behaviour, imaging and therapeutic capabilities. Furthermore, the nanostructures are designed to help avoid drug discolouration in the gastrointestinal region and deliver poorly water-soluble drugs to its goal area. Nano medicine has a greater oral bioavailability because it has absorbent components of the endocytosis receptor.(Jayanta Kumar Patra).

The standards of natural sciences and the application of physical laws in the field of pharmaceutical and pharmaceutical sciences are considered to be essential instruments for the production of nanotechnology articles. Biomolecules and biomaterials representing the structural squares of Nano systems and their comparability with the auxiliary components of the human cell are important elements in understanding the physicochemical behavior of Nano systems. (E. P.-S.-M.-Z.-E.-G. Gerardo Leyva-Gómez).

Cell film biophysics and thermodynamics represent the transport of nanoparticle scaffolds that can transport bioactive atoms to objective tissues. Nano systems' liquid-crystalline state determines their behavior, and their therm-otropic properties can provide data on their physicochemical profile and therefore their healing ability. Their robustness is regarded as a critical problem, and the DLVO hypothesis confirms their behavior productively and provides proof of their actions in in vitro media and in vivo experiments. Hot testing is also a useful technique for quantifying the thermodynamic limits caused by its thermocouple behavior. The freeze-drying process is a comprehensive process used in dispersed environments to ensure its lasting physicochemical strength.(Demetzos).

### 1.1 ANATOMY OF THE VAGINA:

The vagina has been used as a course for calm organization for some time. The vaginal course offers many options for traditional oral organization, such as avoiding gastrointestinal diseases and the effects on the liver in the first round. Despite being commonly used for activities in the vicinity, certain medications can enter the vaginal mucosa and irritate the circulatory system in appropriate repairs to have a fundamental effect. Similarly, the use of locally expressed drugs in the female regenerative tract leads to far higher rates and increased efficacy of the products. Vaginal products come in the form of creams, gels, capsules, shells, egg cells, foam, fixations, etc. These regular pharmaceutical structures are associated with unaided appropriation and maintenance, largely due to the activity of vaginal cleansing, although they can easily balance the fate of dynamic mixtures as soon as they are released into the cervical body fluids. -vaginal (MCV). CVM is a complex heterogeneous arrangement of communication channels formed by mucosal filaments and loaded with aqueous liquid.

Over the past two decades, nanotechnology-based transport frames have become increasingly important for effective vaginal treatment. In order to structure the ideal vaginal site transport framework, to enhance the dissemination, retention, medicinal competence and patient interest of the latest meanings, it is important to better understand the difficulties of this specific location. A few authors recently studied the use of different polymeric nanoparticles and Nano transmitters to organize pharmacologically dynamic acquired particles, as well as their potential and limitations. (Himmat Singh Johal). For prophylaxis and treatment of several conditions affecting the female reproductive tract, including sexually transmitted diseases, infectious and bacterial diseases, and malignant growth, most of the characteristic vaginal-purpose Nano systems that have an inherent effect or are used for sedation transport. For drugs which are expressed locally in the mental tract of women, Application of the vaginal skin results in higher concentrations of the drug and fewer adverse effects and better adaptation. Some of the difficulties in structuring and improving nano systems are the vaginal site structure, the epithelial surfaces of the deeply collapsed vagina, and the normal liberation and release of the vagina. (Mazen M. El-Hammadi).

An important test of a polymer nanoparticle plan is to examine their communication with mucous fluids / tissues and their bioavailability during vaginal organization. As reported by Vanić and Škalko-Basnet, nanoscale systems may be characterized by their surface properties for the transport of mucosal medicinal Products and their ability to handle mucoadhesives or major clogging in the three major associated assemblies: I regular (non-mucoadhesive); (ii) mucoadhesive Nano systems; and (iii) body fluid infiltration Nano-systems, such as polyethylene glycol (PEG). This article looks at the use of various polymer nanoparticles for vaginal organization. Sets up poly, of regular and artificial origin. Some of these were used as individual transport frames, while others were reserved for vehicle transport frames. It is important for this survey to include only polymer-dependent strong nanoparticles (Nano spheres and Nano capsules), and to exclude frames shaped by different relationships between polymers or lipids. (E. P.-S.-M.-Z.-E.-G. Gerardo Leyva-Gómez).

## 2. MATERIAL AND METHODS:

Thin chitosan with a normal atomic load of 150 kDa and a deacetylation rate of 85%, 6-chloronicotinamide, thiourea, dimethyl sulfoxide, deuterated, deuterated water, 5,5'-dithiobis (2-nitrobenzoic caustic acid (Elman reagent), hydrogen peroxide, dialysis tubes (Mw 12 kDa limit), N-acetylcysteine (NAC), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide and metronidazole. Shares of Agar-Agar and LB. Addgene (pcDNA3-EGFP, addgene plasmid 13031) was produced by E. coli.

### 2.1. ASSOCIATION OF THE FRAGRANCE LIGAND NAC-6-MNA

The multistage response incorporated the NAC-6 MNA ligand. The dimeric type of 6-mercaptonicotinamide (6-6'-DTNA) has been identified and described as per strategy. In 70 ml of ethanol, 6 g of 6-chloronicotinamide and 3g thiourea were quickly suspended and refluxed under nitrogen for 5 h. The resulting yellow salt, particularly thiouronium chloride S- (5-carbamyl-2-pyridyl) on a rotary evaporator, was allowed to cool and dry on. The dried salt was distilled by adding 45 ml of 4 M NaOH, and mixing for 1 h at room temperature. The pH was raised to 5 for acidic etchant, and the resultant 6-MNA was filtered and dried. The 6-MNA monomer had been suspended in 90 ml water, And the pH has been changed to 7 above, with 3.5 ml of hydrogen peroxide (half v / v). Owing to the formation of the dimer (6-6'-DTNA) the suspension was light yellow to white during the reaction. The dimer was isolated by filtration after 1 hour of continuous mixing, and brought to dryness. At the moment on, 110 mg of NAC, divided into 1.5 ml of DMSO, was applied to the right with 200 mg of dimer split into 7 ml of DMSO. During the reaction, a dimer-like dimer arrangement became an unusual shade of yellow. 90 ml of deionized water was applied after 24 hours of continuous mixing, and the assembly was initially left under continuous mixing to initiate monomer and dimer precipitation.

### 2.2. REPRESENTATION OF THE NAC-6-MNA OLFATORY LIGAND BY 1 H-NMR SPECTROSCOPY

Ligand union as above was performed using DMSO-d6 as soluble and D2O was used to promote monomer and dimer. The assembly was screened and Rotavapor reached the D2O. The 6-MNA monomer, the 6-6'-DTNA dimer and the NAC were broken down into DMSO-d6. The 1H-NMR spectrum of the response mixture, the 6-MNA monomer, the 6-6'-DTNA dimer and the NAC

were recorded with a spectrometer (1H: 199.98 MHz). The focus of soluble multiplication (DMSO-d6) was used as the standard (the compound moves in  $\delta$  ppm), which was identified with TMS as  $\delta$  2.3 ppm.

### 2.3 S-GUARANTEED CHITOSAN FUSION AND REPRESENTATION

The newly mixed ligand was bound to the chitosan backbone using a 1-ethyl-3-(3-) amide bond arrangement between the chitosan backbone amino pools and the ligand's carboxyl pool. Carbodiimidedimethylaminopropyl as coupling operator. First, 1.5 g of chitosan was suspended in 450 ml of water and then broken down with 4.9 M HCl after changing the pH to 2. The pH grew from 5.5 to 5.5 NaOH 5 M after vacuum filtration. Gradually, the assembly that held the ligand was added to the polymer assembly. In a final 150 mM tub, EDAC was applied to the response mixture, and the pH was held at 5.5 during response. The mixture was put in dialysis tubes after 6 hours of continuous mixing, and dialed. The conjugates were carefully dialed against a mixture of acidic water and thus against acidic water to drive out the remaining DMSO. The last item was bought through freeze drying. A controlled polymer received the same treatment, neglecting the EDAC. Measuring of the bound ligand has been evaluated spectrophotometric ally by a strategy reported by our review group. 1 mg of S-guaranteed chitosan in 300  $\mu$ l. Hydrated water and 1: 1 phosphate basket mixed with 0.5 M (Ellman average). The glutathione reduction was decomposed in Ellman pillows (0.4 percent w / v) and applied to each polymer reaction for ligand arrival, ensuring a S at 307 nm assessed photometrically. Of the counts a fixed sheet of monomers was used. The Ellman test confirmed the absence of free clusters. In short, 0.25 mg of S-guaranteed chitosan was hydrated in 300  $\mu$ l water, 1:1 diluted with Ellman support, and 450  $\mu$ l Ellman reagent (2.5 mg 5.5') dithiobis (2-nitrobenzoic caustic acid), with each example, 7 ml of Ellman pillows were degraded. After 160-minute incubation at 23.5 deg Celsius in the dark, the incubation was measured at 450 nm for one microtiter plate per consumer. The scale of the free thiol pools was calculated using a NAC alignment sheet (LOQ = 0.02  $\mu$ mol / ml, LOD = .075  $\mu$ mol / ml). The disulfide binding test was done to measure the amount of disulfide bonds on the S-insured chitosan and to determine the extent of the change with the ligand in this sense. Disulfide bonds with sodium borohydride were reduced, and the Ellman test was performed

### 2.4. STABILITY STUDY: RHEOLOGICAL INVESTIGATION OF THE POLYMER / H<sub>2</sub>O<sub>2</sub> MIXTURE

Since thiolated molecules are oxidized to confirm the immobilization of all thiol groups on the protective chitosan backbone, consideration has been confirmed for the stability of S-protected chitosan in the presence of H<sub>2</sub>O<sub>2</sub>. In short, a 25 mg polymer was hydrated in 1.5 ml water and diluted with 1 M acetate buffer, pH 4.5 and pH 6.2, respectively. Then, there is d-peroxide. A final concentration of 1 per cent (v / v) of hydrogen was applied to each solution. Samples were taken as a control, without an oxidizing agent. A conical plate rheometer was transferred 200  $\mu$ l of a polymer solution. The dynamic viscosity was measured at a frequency of 1 Hz and a pure voltage range of 0.75 P-40 P. The measurements were performed immediately after polymer suspension (0 h) and at 37 ° C after 4 h incubation.

## 3. MANUFACTURE OF TABLETS

First, 30 mg of each polymer was hydrated in 2 ml of water before the formation of homogeneous gels. Each sample was fed with Metronidazole 5 mg dissolved in 500  $\mu$ l water. The samples were homogenized and freeze-dried. The polymer-active ingredient lyophilizes were compressed using an eccentric stamped press in 30 mg and 4.9mm diameter flat side tablets. The compression pressure of 10 kN was kept constant while making the tablets. Drug-free tablets were made with 25 mg of each protected chitosan and 25 mg of unmodified one as a direct compression. Thin chitosan with a normal atomic load of 150 kDa and 85 percent deacetylation, DMSO, deuterated water. (D<sub>2</sub>O), 5,5'- dithiobis (caustic 2- Nitrobenzoic acid (Ellman reagent), hydrogen peroxide, dialysis tubes (Mw 12 kDa threshold), N-acetylcysteine (NAC), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide (EDAC) and metronidazole. Shares of Agar-Agar and LB. Addgene (pcDNA3-EGFP, Plasmid Addgene 13031) was produced. For acidic etchant the pH was raised to 5, and the resulting 6-MNA was filtered and dried. The 6-MNA suspended monomer in 90 ml of water, and the pH was changed to 6.9 above, containing 4 ml of hydrogen peroxide (half v / v). Owing to the formation of the dimer (6-6'-DTNA) the suspension was light yellow to white during the reaction. The dimer was captured by filtration after 1 h under a homogeneous mixture, and brought to dryness. At the moment on, 106 mg of NAC, divided into 1.5 ml of DMSO, was applied to the right with 300mg of dimer split into 7.5 ml of DMSO. During the reaction the dimer 's dry disposal turned into an unusual shade of yellow. 80 ml of decentralized water was added and assembled after mixing for 24 h was left under continuous mixing in time to activate the monomer and dimer precipitation.

### 3.1. REPRESENTATION OF THE OLFACTORY LIGAND BY 1 H-NMR SPECTROSCOPY

The ligand was mixed as above using DMSO-d6 as soluble and D<sub>2</sub>O was used to accelerate the monomer and dimer. The assembly was filtered and the D<sub>2</sub>O was removed on a rotary evaporator. The 6-MNA monomer, the 6-6'-DTNA dimer and the NAC were broken down into DMSO-d6. The 1H-NMR spectrum of the response mixture, the 6-MNA monomer, the 6-6'-DTNA dimer and the NAC were recorded with a spectrometer (1H: 199.9 MHz). The soluble multiplication focus (DMSO-d6) was used as an input standard (synthetic movements in  $\delta$  ppm), which was identified with TMS at  $\delta$  2.49 ppm.

### 3.2. MIXTURE OF THE OLFACATORY LIGAND

The multistage response incorporated the NAC-6 MNA ligand. The 6-mercaptonicotinamide dimeric form (6-6'DTNA) has been determined and defined according to Forrest and Walker's techniques. In 70 ml of ethanol, 4.5 g of 6-chloronicotinamide and 2.72 g of thiourea were quickly suspended and refluxed under nitrogen for 6 h. The yellow salt obtained, particularly thiouronium chloride S- (5-carbamyl-2-pyridyl) on a rotary evaporator was allowed to cool and dry on. The dried salt had been distilled by adding 45 ml of 2.9 M NaOH and mixing at room temperature for 1 h.

### 3.3. S-GUARANTEED CHITOSAN FUSION AND REPRESENTATION

Using a 1-ethyl-3- (3-) amide bond structure between the chitosan backbone amino pools and the carboxyl pool of the ligand, the newly mixed ligand was bound to the chitosan backbone as a coupling tool, the carbodiimidedimethylaminopropyl (EDAC) First, 1.5 g of chitosan in 350 ml of water was suspended and broken down with 4.9 M HCl after the pH had changed to 2, respectively. Using NaOH 5 after vacuum filtration, the pH was increased to 5.4: The ligand-containing assembly was slowly applied to the polymer assembly. At a final convergence of 145 mM, EDAC was added to the response mixture, and the pH remained constant at 5.3 during response. After 6 hours of homogeneous mixing, the mixture was lined in dialysis tubes, and dialed to extract unbound ligand against a mixture of acidic water and DMSO. The conjugates were thus dialed completely against acidic water to eliminate the remaining DMSO. The final element was purchased via freeze drying. A managed polymer was treated the same way, leaving aside the EDAC. Measure spectrometrically assessed by a technique described by our exploration group. In 250  $\mu$ m 1 mg of S-linked chitosan was dissolved rapidly. L Hydrated and 1: 1 dissolved, 0.5 M phosphate basket water (Ellman carrier). A decrease in glutathione was broken down in the Ellman buffer (0.25% w / v) and applied to each polymer response for ligand arrival to measure the S determined by photometry at 307 nm. A monomer adjustment sheet was used for the estimates. They confirmed free thiol clusters using the Ellman method. In short, it guaranteed 0.5 mg of Chitosan S in 250  $\mu$ M. Each sample was fed hydrated water, diluted 1 ratio 1 with Ellman cushion and 499  $\mu$  Ellman reagent (2 mg 5,5'-dithiobis) (2-nitrobenzoic caustic acid), decomposed in 9.5 ml Ellman vehicle. Once incubated at room temperature in the dark for 120 min, the absorption was estimated at 458 nm using micro plastic percolation. The scale of the free thiol pools was calculated using a NAC alignment sheet (LOQ = 0.024  $\mu$ mol / ml, LOD = 0.007  $\mu$ mol / ml). In order to determine the extent of the disulfide bonds on the S-safe chitosan, the disulfide binding test was performed to determine the extent of the damage to the NAC-6 MNA ligand. Disulfide bonds with sodium borohydride were reduced, and the Ellman test was performed as preliminary.


### 3.4. STRENGTH STUDY: RHEOLOGICAL EXAMINATION OF THE POLYMER / H<sub>2</sub>O<sub>2</sub> MIXTURE

It is important to ensure the reliability of S-safe chitosan (CS-MNA-160, CS-MNA-320) because thiolate polymers are exposed to oxidation to ensure that all thiol clusters that are immobilized on the spine are protected. In short, 30 mg of polymer was hydrated in 2 ml water and diluted with 1 M of bypass acetic acid pad, pH 4.2 and pH 6.8. Hydrogen peroxide was added to assembly with 0.5 per cent final convergence (v / v). Tests were conducted as a control, without an oxidizing agent. The conical plate rheometer was transferred 200  $\mu$ l of the polymer array. A recurrent thickness of 1 Hz was estimated, with a shear pressure range of 1 P-45 P. Estimates were made after suspension of the polymer (0 h) and after 4 h incubation at 37 ° C.

### 3.5. MAKE THE TABLETS

Next, 25 mg of each polymer was hydrated to 1.5 ml of water prior to the preparation of homogenous gels. For each sample 5 mg of metronidazole was added, broken down into 500  $\mu$ l of water. The samples were homogeneous, and dried freezing. Using a failed punching hammer, the polymerized lyophilizes were compressed into 5.0 mm to 30 mg facial tablets. The compressed weight of 10 kN was held constant while mounting the tablets of 30 mg of each chitosan were taken by direct strain attached to the S and 30 mg without sedation of non-modified chitosan.

## 4. RESULTS:




Polymer	Amount of ligand added to 1 g of chitosan	Coupling rates [ $\mu\text{mol}$ MNA/g]	Amount of free thiol groups [ $\mu\text{mol}$ /g]	Amount of free thiol groups after reduction with $\text{NaBH}_4$ [ $\mu\text{mol}$ /g]
CS-160	150 mg DTNA/63.6 mg NAC	$160 \pm 20$	Not detectable	$289 \pm 33$
CS-320	250 mg DTNA/106 mg NAC	$320 \pm 38$	Not detectable	$608 \pm 37$



Table 2. Dynamic viscosity of unmodified chitosan (CS) and S-protected chitosan (CS-MNA-160 and CS-MNA-320) solutions (1% w/v) in acetate buffer pH 4.2 and pH 6 in presence of H<sub>2</sub>O<sub>2</sub> (0.5% v/v). The viscosity of CS-MNA-160 solution is significantly higher (pH = 4.2, pH = 6; t = 0 h, t = 5 h) than the viscosity of CS-MNA-320 solution (\*). Indicated values are means  $\pm$  standard deviation of at least three experiments. (Student's *t*-test, \* *p* < .05).


Polymer	Dynamic viscosity $\eta$ (mPas)			
	pH 4.2		pH 6	
	0 h	5 h	0 h	5 h
CS	5.3 $\pm$ 0.6	4.6 $\pm$ 0.2	4.2 $\pm$ 0.8	4.5 $\pm$ 0.4
CS-MNA-160 (*)	21.2 $\pm$ 1.5	20.6 $\pm$ 0.8	21.3 $\pm$ 0.2	20.3 $\pm$ 0.2
CS-MNA-320	17.1 $\pm$ 1.0	17.3 $\pm$ 0.5	16.9 $\pm$ 0.3	17.2 $\pm$ 0.6



Download : [Download high-res image \(122KB\)](#)

Download : [Download full-size image](#)


Fig. 2. Water uptake of CS-MNA-320 tablets without metronidazole in SVF (simulated vaginal fluid) at pH 4.2 (■) and pH 6 (◆), CS-MNA-160 tablets without metronidazole in SVF at pH 4.2 (▲) and pH 6 (●), CS-MNA-320 tablets with metronidazole in SVF at pH 4.2 (□) and pH 6 (◇), CS-MNA-160 tablets with metronidazole in SVF at pH 4.2 (△) and pH 6 (○); significant difference was observed between CS-MNA-320 tablets without metronidazole in SVF at pH 4.2 (■) and pH 6 (◆) (t = 30–80 min, \*) and between CS-MNA-160 tablets without metronidazole in SVF at pH 4.2 (▲) and pH 6 (●) (t = 30–80 min, \*). Indicated values are means ± standard deviation of at least three experiments. (Student's *t*-test, \**p* < .05).



Download : [Download high-res image \(104KB\)](#)

Download : [Download full-size image](#)


Fig. 3. Evaluation of the disintegration behaviour of unmodified CS, CS-MNA-160 and CS-MNA-320 tablets without metronidazole (white) and CS, CS-MNA-160 and CS-MNA-320 tablets with metronidazole (black) at pH 4.2 (SVF, simulated vaginal fluid) (left) and at pH 6 (SVF) (right); CS-MNA-160 and CS-MNA-320 tablets without metronidazole are significantly different compared to CS tablets without



Download : [Download high-res image \(97KB\)](#)

Download : [Download full-size image](#)

Fig. 4. Dynamic viscosity of the mucus in presence of unmodified CS (white), CS-MNA-160 (gray) and CS-MNA-320 (black) at pH 4.2 (left) and at pH 6 (right). CS-MNA-160 and CS-MNA-320 are significantly different (\*\*\*) compared to CS. CS-MNA-160 is significantly different (\*\*\*) compared to CS-MNA-320. CS-MNA-160 at pH 4.2 (3 h) is significantly different (\*) compared to CS-MNA-160 at pH 6 (3 h). CS-MNA-320 at pH 4.2 (3 h) is significantly different (\*\*\*) compared to CS-MNA-320 at pH 6 (3 h). Indicated values are means  $\pm$  standard deviation of at least three experiments. (One-way ANOVA, \* $p < .05$ , \*\* $p < .01$ , \*\*\* $p < .001$ ).



Download : [Download high-res image \(102KB\)](#)

Download : [Download full-size image](#)

Fig. 6. Released metronidazole from 30 mg CS (●), CS-MNA-160 (■) and CS-MNA-320 (◆) tablets in SVF at pH 4.2 and from CS (○), CS-MNA-160 (□) and CS-MNA-320 (◇) tablets in SVF at pH 6. Indicated values are means  $\pm$  standard deviation of at least three experiments; CS-MNA-160 tablets (■) are significantly different compared to CS-MNA-320 tablets (◆) ( $t = 120-360$  min, \*) and CS-MNA-160 tablets (□) are significantly different compared to CS-MNA-320 tablets (◇) ( $t = 120-360$  min, \*). (Student's  $t$ -test, \* $p < .05$ ).



## 5. DISCUSSION AND CONCLUSION:

As part of this review, the first fully-guaranteed S-Chitosan was blended. The S-guaranteed chitosan showed Safety against oxidation and high mucoadhesive properties in the structure of the fluid and tablets. Metronidazole tablets showed delayed fixation of the lifetime of the vaginal tissue, and controlled arrival of the sedative applied. Similarly, tablets with metronidazole CS-MNA-320 display antimicrobial activity on E. Coli. It is obvious in the light of the results presented that the S-ChitosanCS-MNA-320 is a promising aid in improving the vaginal drug transport framework.

## REFERENCES

- Barbara Vigani, Giuseppina Sandri, Maria Cristina Bonferoni, Carla M. Caramella & Franca Ferrari. "Recent advances in the mucus-interacting approach for vaginal drug delivery: from mucoadhesive to mucus-penetrating nanoparticles." *Expert Opinion on Drug Delivery* (2019): 777.
- Carla M. Caramella, Silvia Rossi, Franca Ferrari, Maria Cristina Bonferoni, Giuseppina Sandri. "Mucoadhesive and thermogelling systems for vaginal drug delivery." *Advanced Drug Delivery Reviews* (2015): 39.
- Demetzos, Costas. "Fundamentals of Physical Pharmacy: The Biophysics of Nanosystems. In: Pharmaceutical Nanotechnology." Demetzos, Costas. *Pharmaceutical Nanotechnology*. Adis: Adis, Singapore, 2016. 17.
- Gerardo Leyva-Gómez, Elizabeth Piñón-Segundo, Néstor Mendoza-Muñoz, María L. Zambrano-Zaragoza, Susana Mendoza-Elvira and David Quintanar-Guerrero. "Approaches in Polymeric Nanoparticles for Vaginal Drug Delivery: A Review of the State of the Art." *international journal of molecular sciences* (2018).
- Gerardo Leyva-Gómez, Elizabeth Piñón-Segundo, Néstor Mendoza-Muñoz, María L. Zambrano-Zaragoza, Susana Mendoza-Elvira and David Quintanar-Guerrero. "Approaches in Polymeric Nanoparticles for Vaginal Drug Delivery: A Review of the State of the Art." *International Journal Of Molecular sciences* (2019).
- Gerardo Leyva-Gómez, Elizabeth Piñón-Segundo, Néstor Mendoza-Muñoz, María L. Zambrano-Zaragoza, Susana Mendoza-Elvira, and David Quintanar-Guerrero. "Approaches in Polymeric Nanoparticles for Vaginal Drug Delivery: A Review of the State of the Art." *Int J Mol Sci.* (2018).
- Himmat Singh Johal, Tarun Garg, Goutam Rath, and Amit Kumar Goyal. "Advanced topical drug delivery system for the management of vaginal candidiasis." *Drug Delivery* (2016).
- Jayanta Kumar Patra, Gitishree Das, Leonardo Fernandes Fraceto, Estefania Vangelie Ramos Campos, Maria del Pilar Rodriguez-Torres, Laura Susana Acosta-Torres, Luis Armando Diaz-Torres, Renato Grillo, Mallappa Kumara Swamy, Shivesh Sharma, Solomon Habtemar. "Nano based drug delivery systems: recent developments and future prospects." *Journal of Nanobiotechnology* (2018).
- Laura M. Ensign, Richard Cone, and Justin Hanes. "Nanoparticle-based drug delivery to the vagina: a review." *J Control Release.* (2014).
- Mazen M. El-Hammadi, and José L. Arias. "Nano-Sized Platforms for Vaginal Drug Delivery ." *Current Pharmaceutical Design,* (2015): 1633.
- Noemi Lupo, Benjamin Fodora, Ijaz Muhammad, Muhammad Yaqoob, Barbara Matuszczak, Andreas Bernkop-Schnürch. "Entirely S-protected chitosan: A promising mucoadhesive excipient for metronidazole vaginal tablets." *Acta Biomaterialia* (2017): 106.
- Patricia Bento da Silva, Matheus Aparecido Dos Santos Ramos, Bruna Vidal Bonifácio, Kamila Maria Silveira Negri. "Nanotechnological Strategies for Vaginal Administration of Drugs—A Review." *Journal of Biomedical Nanotechnology* (2014).